



**MHRA**

10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

[REDACTED]

UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST  
SOUTHAMPTON GENERAL HOSPITAL,  
TREMONA ROAD  
SOUTHAMPTON  
SO16 6YD  
UNITED KINGDOM

17/05/2021

Dear [REDACTED]

**THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031**

|                  |   |
|------------------|---|
| Our Reference:   | CTA 11709/0279/001-0001   |
| Eudract Number:  | 2021-002175-19  |
| Product:         | Comirnaty, ChadOx1 nCov-19/AZD1222, COVID-19<br>Vaccine Moderna, NVX-CoV2373, VLA2001, CVnCoV,<br>Nimenrix, Menveo, Ad26.COV2.S |
| Protocol number: | RHM MED1781   |

**NOTICE OF ACCEPTANCE**

I am writing to inform you that the Licensing Authority accepts your request for a clinical trial authorisation (CTA), received on 06/05/2021.

The authorisation is effective from the date of this letter although your trial may be suspended or terminated at any time by the Licensing Authority in accordance with regulation 31. You must notify the Licensing Authority within 90 days of the trial ending.

You are reminded that a favourable opinion from the Ethics Committee is also required before this trial can proceed. If not already provided, please follow the guidance on our website on informing us of the registration status of your trial (where applicable).

*You are reminded that from 1 January 2022 you will need to comply with the requirements specified in the following guidance, where applicable:*

- o Import of IMPs from listed countries to GB:*



<https://www.gov.uk/government/publications/importing-investigational-medicinal-products-into-great-britain-from-approved-countries>

o *Supply of IMPs to Northern Ireland:*

<https://www.gov.uk/guidance/supplying-investigational-medicinal-products-to-northern-ireland>

o *Substantial amendments to clinical trials:*

<https://www.gov.uk/guidance/guidance-on-substantial-amendments-to-a-clinical-trial>

*Any required substantial amendment to your Clinical Trial Authorisation should be submitted and approved as soon as possible and before 1 January 2022.*

Yours sincerely,

Clinical Trials Unit  
MHRA